The Facioscapulohumeral Muscular Dystrophy Rasch‐Built Overall Disability Scale ( FSHD ‐ RODS ): Longitudinal Assessment of a Disease‐Specific Patient Reported Outcome
European Journal of Neurology · 2025-08 · 32 (8)
DOI: 10.1111/ene.70238 ↗At a glance
Journal article in European Journal of Neurology, published online on 2025-08-09. Written by Sjan Teeselink and 5 co-authors. Institution: Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, the Netherlands. Major MEDLINE topics: Muscular Dystrophy, Facioscapulohumeral, Patient Reported Outcome Measures, Disability Evaluation. Cited 6 times so far (Crossref); 32 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Prinses Beatrix Spierfonds, FSHD Stichting.
Abstract (original language)
Objective
To assess changes in the facioscapulohumeral muscular dystrophy Rasch‐Built Overall Disability Scale (FSHD‐RODS) over 6.5 years in FSHD patients.
Methods
FSHD patients of 18 years or older were assessed at baseline (T1) and followed up at 5 years (T2) and 6.5 years (T3). The patient‐reported FSHD‐RODS and Sickness Impact Profile 68 (SIP68) questionnaires were evaluated, alongside the FSHD clinical severity score, FSHD clinical score and Motor Function Measure (MFM). Individual minimal clinically important differences (MCID‐SE) of the FSHD‐RODS were calculated to assess the clinical importance of the change over time. A subgroup analysis included patients eligible for current clinical trials.
Results
Sixty‐two patients were included, representing the full disease spectrum. The FSHD‐RODS and SIP68 questionnaire outcomes remained stable, whereas overall disease severity slightly increased (FSHD clinical severity score 6 to 6.5, p < 0.001) and MFM slightly decreased (94% to 91%, p < 0.001). FSHD‐RODS correlated strongly with SIP68, MFM and disease severity ( ρ ≥ 0.69). The clinical trial subgroup ( n = 33) showed similar results. Ten patients (16%), all with moderate–to‐severe baseline disease (FSHD clinical severity score ≥ 6), showed clinically important deterioration over 6.5 years.
Conclusions
FSHD progression is generally slow, with FSHD‐RODS only detecting meaningful decline in moderately to severely affected patients. The ability to compensate for muscle weakness may limit the sensitivity of patient‐reported outcomes like FSHD‐RODS in clinical trials. These findings highlight the need for alternative measures to capture disease progression and treatment effects in FSHD research.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, the Netherlands.
ORCID profiles: Sjan Teeselink, Sanne C C Vincenten, Karlien Mul
Funding
- Prinses Beatrix Spierfonds
- FSHD Stichting
Cite
APA
Teeselink, S., Vincenten, S. C. C., Voermans, N. C., van Alfen, N., van Engelen, B. G. M., & Mul, K. (2025). The Facioscapulohumeral Muscular Dystrophy Rasch‐Built Overall Disability Scale ( FSHD ‐ RODS ): Longitudinal Assessment of a Disease‐Specific Patient Reported Outcome. European Journal of Neurology, 32(8). https://doi.org/10.1111/ene.70238
Vancouver
Teeselink S, Vincenten SCC, Voermans NC, van Alfen N, van Engelen BGM, Mul K. The Facioscapulohumeral Muscular Dystrophy Rasch‐Built Overall Disability Scale ( FSHD ‐ RODS ): Longitudinal Assessment of a Disease‐Specific Patient Reported Outcome. European Journal of Neurology. 2025;32(8). doi:10.1111/ene.70238
BibTeX
@article{Teeselink2025,
author = {Teeselink, Sjan and Vincenten, Sanne C C and Voermans, Nicol C and van Alfen, Nens and van Engelen, Baziel G M and Mul, Karlien},
title = {The Facioscapulohumeral Muscular Dystrophy Rasch‐Built Overall Disability Scale ( FSHD ‐ RODS ): Longitudinal Assessment of a Disease‐Specific Patient Reported Outcome},
journal = {European Journal of Neurology},
year = {2025},
volume = {32},
number = {8},
doi = {10.1111/ene.70238}
}
EUVIMED